The investment objective is to provide above average capital growth over the medium to long term by investment in a portfolio of the securities of companies in any European country, including Turkey, but excluding the United Kingdom.
Name | % Net Assets |
---|---|
Novartis | 5.2% |
Roche Holdings Genusscheine | 4.7% |
Banco Santander | 4.6% |
Nestle | 4.1% |
Unicredit | 3.5% |
SAP | 3.3% |
Bayer | 3.2% |
ABB | 3.1% |
Carrefour | 3.0% |
E.on | 3.0% |
Key | % Net Assets |
---|---|
Novartis | 5.2% |
Roche Holdings Genusscheine | 4.7% |
Banco Santander | 4.6% |
Nestle | 4.1% |
Other | 81.4% |
Date | 21-Nov-2024 |
---|---|
NAV | 216.20p |
Currency | GBP |
Change | -0.50p |
% | -0.23% |
YTD change | -3.10p |
YTD % | -1.41% |
Fund Inception | 31/01/2000 |
---|---|
Fund Manager | Thomas Digenen (UBS Asset Management Ltd) |
TER | - |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £500 |
Savings | £50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.38% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research